{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:56:03Z","timestamp":1789689363861,"version":"4.0.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T00:00:00Z","timestamp":1585267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T00:00:00Z","timestamp":1585267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Neisseria gonorrhoeae<\/jats:italic> represents an urgent public health threat due to the rapid emergence of resistance to current antibiotics and the limited number of anti-gonococcal agents currently in clinical trials. This study utilized a drug repositioning strategy to investigate FDA-approved gold-containing drugs against <jats:italic>N. gonorrhoeae<\/jats:italic>. Auranofin, sodium aurothiomalate and aurothioglucose inhibited 48 clinical isolates of <jats:italic>N. gonorrhoeae<\/jats:italic> including multidrug-resistant strains at a concentration as low as 0.03\u2009\u00b5g\/mL. A time-kill assay revealed that auranofin exhibited rapid bactericidal activity against <jats:italic>N. gonorrhoeae<\/jats:italic>. Moreover, both sodium aurothiomalate and aurothioglucose did not inhibit growth of vaginal protective commensal lactobacilli. Auranofin, in combination with azithromycin, ceftriaxone, cefixime or tetracycline showed an additive effect against four <jats:italic>N. gonorrhoeae<\/jats:italic> strains, suggesting the possibility of using auranofin in dual therapy. Moreover, auranofin reduced the burden of intracellular <jats:italic>N. gonorrhoeae<\/jats:italic> by over 99% outperforming the drug of choice ceftriaxone. Auranofin was found superior to ceftriaxone in reducing the secretion of the pro-inflammatory cytokine IL-8 by endocervical cells infected with <jats:italic>N. gonorrhoeae<\/jats:italic>. Furthermore, auranofin exhibited a prolonged post-antibiotic effect over 10\u2009h, as well as inability to generate resistant mutants. Overall, the current study suggests that repurposing gold-containing drugs, like auranofin, for treatment of gonorrhea warrants further investigation.<\/jats:p>","DOI":"10.1038\/s41598-020-62696-3","type":"journal-article","created":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T11:03:11Z","timestamp":1585306991000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Investigation of auranofin and gold-containing analogues antibacterial activity against multidrug-resistant Neisseria gonorrhoeae"],"prefix":"10.1038","volume":"10","author":[{"given":"Ahmed","family":"Elkashif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed N.","family":"Seleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,27]]},"reference":[{"key":"62696_CR1","unstructured":"Control, C. f. D. & Prevention. Antibiotic resistance threats in the United States, 2013. (Centres for Disease Control and Prevention, US Department of Health and \u2026, 2013)."},{"key":"62696_CR2","unstructured":"World Health Organization. Emergence of multi-drug resistant Neisseria gonorrhoeae: Threat of global rise in untreatable sexually transmitted infections, 2011)."},{"key":"62696_CR3","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1128\/CMR.17.4.965-981.2004","volume":"17","author":"JL Edwards","year":"2004","unstructured":"Edwards, J. L. & Apicella, M. A. The molecular mechanisms used by Neisseria gonorrhoeae to initiate infection differ between men and women. Clinical microbiology reviews 17, 965\u2013981 (2004).","journal-title":"Clinical microbiology reviews"},{"key":"62696_CR4","first-page":"197","volume":"3","author":"CK Walker","year":"2011","unstructured":"Walker, C. K. & Sweet, R. L. Gonorrhea infection in women: prevalence, effects, screening, and management. Int j. Womens Health 3, 197 (2011).","journal-title":"Int j. Womens Health"},{"key":"62696_CR5","first-page":"793","volume":"27","author":"C Mitchell","year":"2013","unstructured":"Mitchell, C. & Prabhu, M. Pelvic inflammatory disease: current concepts in pathogenesis, diagnosis and treatment. Infectious Disease Clinics 27, 793\u2013809 (2013).","journal-title":"Infectious Disease Clinics"},{"key":"62696_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.tripleo.2005.05.077","volume":"101","author":"JW Little","year":"2006","unstructured":"Little, J. W. Gonorrhea: update. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 101, 137\u2013143 (2006).","journal-title":"Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology"},{"key":"62696_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/0956462412472837","volume":"24","author":"C Bignell","year":"2013","unstructured":"Bignell, C., Unemo, M. & Board, E. S. G. E. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. International journal of STD & AIDS 24, 85\u201392 (2013).","journal-title":"International journal of STD & AIDS"},{"key":"62696_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1258\/ijsa.2011.011267","volume":"22","author":"C Bignell","year":"2011","unstructured":"Bignell, C. & FitzGerald, M. UK national guideline for the management of gonorrhoea in adults, 2011. International journal of STD & AIDS 22, 541\u2013547 (2011).","journal-title":"International journal of STD & AIDS"},{"key":"62696_CR9","unstructured":"(WHO), W. H. O. Guidelines for the Treatment of Neisseria gonorrhoeae, http:\/\/www.who.int\/reproductivehealth\/publications\/rtis\/gonorrhoea-treatment-guidelines\/en\/."},{"key":"62696_CR10","unstructured":"Alliance, A. S. H. Australian STI Management Guidelines for Use in Primary Care., http:\/\/www.sti.guidelines.org.au\/sexually-transmissible-infections\/gonorrhoea."},{"key":"62696_CR11","unstructured":"England, P. H. UK case of Neisseria gonorrhoeae with high-level resistance to azithromycin and resistance to ceftriaxone acquired abroad. Health Protection Report 12 (2018)."},{"key":"62696_CR12","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1056\/NEJMc1512757","volume":"374","author":"H Fifer","year":"2016","unstructured":"Fifer, H. et al. Failure of dual antimicrobial therapy in treatment of gonorrhea. New England Journal of Medicine 374, 2504\u20132506 (2016).","journal-title":"New England Journal of Medicine"},{"key":"62696_CR13","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1056\/NEJMp1112456","volume":"366","author":"GA Bolan","year":"2012","unstructured":"Bolan, G. A., Sparling, P. F. & Wasserheit, J. N. The emerging threat of untreatable gonococcal infection. The New England journal of medicine 366, 485 (2012).","journal-title":"The New England journal of medicine"},{"key":"62696_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.tim.2013.12.007","volume":"22","author":"TF Sch\u00e4berle","year":"2014","unstructured":"Sch\u00e4berle, T. F. & Hack, I. M. Overcoming the current deadlock in antibiotic research. Trends in microbiology 22, 165\u2013167 (2014).","journal-title":"Trends in microbiology"},{"key":"62696_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-26674-0","volume":"8","author":"A AbdelKhalek","year":"2018","unstructured":"AbdelKhalek, A., Abutaleb, N. S., Elmagarmid, K. A. & Seleem, M. N. Repurposing auranofin as an intestinal decolonizing agent for vancomycin-resistant enterococci. Scientific reports 8, 8353 (2018).","journal-title":"Scientific reports"},{"key":"62696_CR16","first-page":"4","volume":"7","author":"S Thangamani","year":"2017","unstructured":"Thangamani, S. et al. Repurposing approach identifies auranofin with broad spectrum antifungal activity that targets Mia40-Erv1 pathway. Frontiers in cellular and infection microbiology 7, 4 (2017).","journal-title":"Frontiers in cellular and infection microbiology"},{"key":"62696_CR17","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jsb.2016.02.015","volume":"194","author":"D Parsonage","year":"2016","unstructured":"Parsonage, D. et al. X-ray structures of thioredoxin and thioredoxin reductase from Entamoeba histolytica and prevailing hypothesis of the mechanism of Auranofin action. Journal of structural biology 194, 180\u2013190 (2016).","journal-title":"Journal of structural biology"},{"key":"62696_CR18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ijantimicag.2015.12.016","volume":"47","author":"S Thangamani","year":"2016","unstructured":"Thangamani, S., Mohammad, H., Abushahba, M. F., Sobreira, T. J. & Seleem, M. N. Repurposing auranofin for the treatment of cutaneous staphylococcal infections. International journal of antimicrobial agents 47, 195\u2013201, https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.12.016 (2016).","journal-title":"International journal of antimicrobial agents"},{"key":"62696_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/srep22571","volume":"6","author":"S Thangamani","year":"2016","unstructured":"Thangamani, S. et al. Antibacterial activity and mechanism of action of auranofin against multi-drug resistant bacterial pathogens. Sci. Rep. 6, 22571, https:\/\/doi.org\/10.1038\/srep22571 (2016).","journal-title":"Sci. Rep."},{"key":"62696_CR20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ijantimicag.2018.09.018","volume":"53","author":"A AbdelKhalek","year":"2019","unstructured":"AbdelKhalek, A., Abutaleb, N. S., Mohammad, H. & Seleem, M. N. Antibacterial and antivirulence activities of auranofin against Clostridium difficile. International journal of antimicrobial agents 53, 54\u201362, https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.09.018 (2019).","journal-title":"International journal of antimicrobial agents"},{"key":"62696_CR21","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1093\/jac\/dkw288","volume":"71","author":"M Unemo","year":"2016","unstructured":"Unemo, M. et al. The novel 2016 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations: phenotypic, genetic and reference genome characterization. Journal of Antimicrobial Chemotherapy 71, 3096\u20133108 (2016).","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"62696_CR22","first-page":"1","volume":"64","author":"KA Workowski","year":"2015","unstructured":"Workowski, K. A. & Bolan, G. A. Sexually transmitted diseases treatment guidelines. 2015. MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports 64, 1 (2015).","journal-title":"2015. MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports"},{"key":"62696_CR23","doi-asserted-by":"publisher","first-page":"S759","DOI":"10.1093\/cid\/civ771","volume":"61","author":"KA Workowski","year":"2015","unstructured":"Workowski, K. A. Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines. Clinical Infectious Diseases 61, S759\u2013S762 (2015).","journal-title":"Clinical Infectious Diseases"},{"key":"62696_CR24","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/infdis\/172.1.186","volume":"172","author":"KH Ramsey","year":"1995","unstructured":"Ramsey, K. H. et al. Inflammatory Cytokines Produced in Response to Experimental Human Gonorrhea. J. Infect. Dis. 172, 186\u2013191, https:\/\/doi.org\/10.1093\/infdis\/172.1.186 (1995).","journal-title":"J. Infect. Dis."},{"key":"62696_CR25","doi-asserted-by":"crossref","unstructured":"Bj\u00f6rkholm, B. et al. Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori. 98, 14607\u201314612 (2001).","DOI":"10.1073\/pnas.241517298"},{"key":"62696_CR26","doi-asserted-by":"crossref","unstructured":"Binet, R., Maurelli, A. T. J. A. A. & chemotherapy. Frequency of development and associated physiological cost of azithromycin resistance in Chlamydia psittaci 6BC and C. trachomatis L2. 51, 4267\u20134275 (2007).","DOI":"10.1128\/AAC.00962-07"},{"key":"62696_CR27","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrmicro.2017.169","volume":"16","author":"SJ Quillin","year":"2018","unstructured":"Quillin, S. J. & Seifert, H. S. Neisseria gonorrhoeae host adaptation and pathogenesis. Nature Reviews Microbiology 16, 226 (2018).","journal-title":"Nature Reviews Microbiology"},{"key":"62696_CR28","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s10156-004-0348-9","volume":"10","author":"S Singh","year":"2004","unstructured":"Singh, S. & Sivakumar, R. Challenges and new discoveries in the treatment of leishmaniasis. Journal of infection and chemotherapy 10, 307\u2013315 (2004).","journal-title":"Journal of infection and chemotherapy"},{"key":"62696_CR29","first-page":"277","volume":"40","author":"CL Ventola","year":"2015","unstructured":"Ventola, C. L. The antibiotic resistance crisis: part 1: causes and threats. Pharmacy and therapeutics 40, 277 (2015).","journal-title":"Pharmacy and therapeutics"},{"key":"62696_CR30","doi-asserted-by":"publisher","first-page":"e0130385","DOI":"10.1371\/journal.pone.0130385","volume":"10","author":"H Mohammad","year":"2015","unstructured":"Mohammad, H. et al. Antibacterial characterization of novel synthetic thiazole compounds against methicillin-resistant Staphylococcus pseudintermedius. PloS one 10, e0130385 (2015).","journal-title":"PloS one"},{"key":"62696_CR31","first-page":"451","volume":"18","author":"ME Levison","year":"2004","unstructured":"Levison, M. E. Pharmacodynamics of antimicrobial drugs. Infectious Disease. Clinics 18, 451\u2013465 (2004).","journal-title":"Clinics"},{"key":"62696_CR32","doi-asserted-by":"publisher","first-page":"4680","DOI":"10.1073\/pnas.1002611107","volume":"108","author":"J Ravel","year":"2011","unstructured":"Ravel, J. et al. Vaginal microbiome of reproductive-age women. Proceedings of the National Academy of Sciences 108, 4680\u20134687 (2011).","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"62696_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-015-0608-0","volume":"15","author":"LM Breshears","year":"2015","unstructured":"Breshears, L. M., Edwards, V. L., Ravel, J. & Peterson, M. L. Lactobacillus crispatus inhibits growth of Gardnerella vaginalis and Neisseria gonorrhoeae on a porcine vaginal mucosa model. BMC microbiology 15, 276 (2015).","journal-title":"BMC microbiology"},{"key":"62696_CR34","doi-asserted-by":"publisher","first-page":"7169","DOI":"10.1128\/IAI.70.12.7169-7171.2002","volume":"70","author":"DCS Amant","year":"2002","unstructured":"Amant, D. C. S., Valentin-Bon, I. E. & Jerse, A. E. Inhibition of Neisseria gonorrhoeae by Lactobacillus species that are commonly isolated from the female genital tract. Infection and immunity 70, 7169\u20137171 (2002).","journal-title":"Infection and immunity"},{"key":"62696_CR35","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1128\/IAI.19.2.704-710.1978","volume":"19","author":"JH Saigh","year":"1978","unstructured":"Saigh, J. H., Sanders, C. C. & Sanders, W. Inhibition of Neisseria gonorrhoeae by aerobic and facultatively anaerobic components of the endocervical flora: evidence for a protective effect against infection. Infection and immunity 19, 704\u2013710 (1978).","journal-title":"Infection and immunity"},{"key":"62696_CR36","first-page":"133","volume":"219","author":"P Lu","year":"2018","unstructured":"Lu, P. et al. A subpopulation of intracellular Neisseria gonorrhoeae escapes autophagy-mediated killing inside epithelial cells. The Journal of infectious diseases 219, 133\u2013144 (2018).","journal-title":"The Journal of infectious diseases"},{"key":"62696_CR37","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ejmech.2018.02.031","volume":"148","author":"MM Elsebaei","year":"2018","unstructured":"Elsebaei, M. M. et al. Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA). European journal of medicinal chemistry 148, 195\u2013209 (2018).","journal-title":"European journal of medicinal chemistry"},{"key":"62696_CR38","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2217\/fmb.11.36","volume":"6","author":"RR Spurbeck","year":"2011","unstructured":"Spurbeck, R. R. & Arvidson, C. G. Lactobacilli at the front line of defense against vaginally acquired infections. Future microbiology 6, 567\u2013582 (2011).","journal-title":"Future microbiology"},{"key":"62696_CR39","first-page":"67","volume":"63","author":"JR Blodgett","year":"1986","unstructured":"Blodgett, J. R. & Pietrusko, R. Long-term efficacy and safety of auranofin: a review of clinical experience. Scandinavian journal of rheumatology. Supplement 63, 67\u201378 (1986).","journal-title":"Scandinavian journal of rheumatology. Supplement"},{"key":"62696_CR40","doi-asserted-by":"publisher","first-page":"e01947","DOI":"10.1128\/AAC.01947-16","volume":"61","author":"EV Capparelli","year":"2017","unstructured":"Capparelli, E. V., Bricker-Ford, R., Rogers, M. J., McKerrow, J. H. & Reed, S. L. Phase I clinical trial results of auranofin, a novel antiparasitic agent. Antimicrobial agents and chemotherapy 61, e01947\u201301916 (2017).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"62696_CR41","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1093\/jac\/dkp098","volume":"63","author":"M Unemo","year":"2009","unstructured":"Unemo, M., Fasth, O., Fredlund, H., Limnios, A. & Tapsall, J. Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. Journal of Antimicrobial Chemotherapy 63, 1142\u20131151 (2009).","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"62696_CR42","doi-asserted-by":"crossref","unstructured":"Alhashimi, M., Mayhoub, A. & Seleem, M. N. Repurposing salicylamide for combating multidrug-resistant Neisseria gonorrhoeae. Antimicrobial Agents and Chemotherapy, AAC. 01225\u201301219 (2019).","DOI":"10.1128\/AAC.01225-19"},{"key":"62696_CR43","unstructured":"CLSI. (9th ed. M07-A9, 2012)."},{"key":"62696_CR44","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.1128\/JCM.43.9.4321-4327.2005","volume":"43","author":"M Takei","year":"2005","unstructured":"Takei, M., Yamaguchi, Y., Fukuda, H., Yasuda, M. & Deguchi, T. Cultivation of Neisseria gonorrhoeae in liquid media and determination of its in vitro susceptibilities to quinolones. Journal of clinical microbiology 43, 4321\u20134327 (2005).","journal-title":"Journal of clinical microbiology"},{"key":"62696_CR45","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ijfoodmicro.2009.03.012","volume":"132","author":"A Kushiro","year":"2009","unstructured":"Kushiro, A. et al. Antimicrobial susceptibility testing of lactic acid bacteria and bifidobacteria by broth microdilution method and Etest. International journal of food microbiology 132, 54\u201358, https:\/\/doi.org\/10.1016\/j.ijfoodmicro.2009.03.012 (2009).","journal-title":"International journal of food microbiology"},{"key":"62696_CR46","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1128\/AAC.00999-09","volume":"54","author":"J Meletiadis","year":"2010","unstructured":"Meletiadis, J., Pournaras, S., Roilides, E. & Walsh, T. J. Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus. Antimicrobial agents and chemotherapy 54, 602\u2013609 (2010).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"62696_CR47","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/nature13445","volume":"510","author":"AM King","year":"2014","unstructured":"King, A. M. et al. Aspergillomarasmine A overcomes metallo-\u03b2-lactamase antibiotic resistance. Nature 510, 503 (2014).","journal-title":"Nature"},{"key":"62696_CR48","doi-asserted-by":"publisher","first-page":"e00826","DOI":"10.1128\/AAC.00826-18","volume":"62","author":"JD Lenz","year":"2018","unstructured":"Lenz, J. D., Shirk, K. A., Jolicoeur, A. & Dillard, J. P. Selective inhibition of Neisseria gonorrhoeae by a dithiazoline in mixed infections with Lactobacillus gasseri. Antimicrobial agents and chemotherapy 62, e00826\u201300818 (2018).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"62696_CR49","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/0140-6736(93)90417-F","volume":"341","author":"A Telenti","year":"1993","unstructured":"Telenti, A. et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. The Lancet 341, 647\u2013651 (1993).","journal-title":"The Lancet"},{"key":"62696_CR50","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/ja.2014.105","volume":"67","author":"RH Baltz","year":"2014","unstructured":"Baltz, R. H. Spontaneous and induced mutations to rifampicin, streptomycin and spectinomycin resistances in actinomycetes: mutagenic mechanisms and applications for strain improvement. The Journal of antibiotics 67, 619\u2013624 (2014).","journal-title":"The Journal of antibiotics"},{"key":"62696_CR51","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1128\/AAC.47.3.1140-1142.2003","volume":"47","author":"G Pankuch","year":"2003","unstructured":"Pankuch, G., Jacobs, M. & Appelbaum, P. Postantibiotic effects of garenoxacin (BMS-284756) against 12 gram-positive or-negative organisms. Antimicrobial agents and chemotherapy 47, 1140\u20131142 (2003).","journal-title":"Antimicrobial agents and chemotherapy"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-62696-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-62696-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-62696-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T08:54:37Z","timestamp":1670316877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-62696-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,27]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["62696"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-62696-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,27]]},"assertion":[{"value":"11 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5602"}}